sharon sanders
Editor-in-Chief & President
[SIZE=-1] Clinical and Vaccine Immunology, December 2007, p. 1592-1595, Vol. 14, No. 12
1071-412X/07/$08.00+0 doi:10.1128/CVI.00313-07
Copyright ? 2007, American Society for Microbiology. All Rights Reserved. [/SIZE]
Use of a Newly Developed β-Mercaptoethanol Enzyme-Linked Immunosorbent Assay To Diagnose Visceral Leishmaniasis in Patients in Eastern Sudan<sup>
</sup>
Durria Mansour, Elfadil M. Abass, Mohamed el Mutasim,<sup>
</sup> Abdelhafeiz Mahamoud, and Abdallah el Harith<sup>*</sup> Ahfad University for Women, P.O. Box 167, Omdurman, Sudan
Received 26 July 2007/ Returned for modification 12 September 2007/ Accepted 2 October 2007
<!-- ABS --> Corroboration of serology results is essential for restricting<sup> </sup>the risk of inappropriate antileishmanial prescription. A direct<sup> </sup>agglutination test (DAT) and a recently developed β-mercaptoethanol-modified<sup> </sup>enzyme-linked immunosorbent assay (β-ME ELISA) based on<sup> </sup>the use of antigen prepared as described for the DAT were applied<sup> </sup>to 416 sera from two Sudanese populations with and without clinical<sup> </sup>evidence of visceral leishmaniasis (VL). Of 285 sera with the<sup> </sup>lowest antileishmanial DAT titers (
1:100 to 1:1,600), 270 (94.7%)<sup> </sup>scored comparable minimum β-ME ELISA absorbance values<sup> </sup>(
0.1 to 0.26). In 117 sera that demonstrated the highest DAT<sup> </sup>titers (1:12,800 to
1:25,600), 86 (73.5%) scored maximum (0.81<sup> </sup>to
1.35) and 30 (25.6%) medium (0.27 to 0.80) β-ME ELISA<sup> </sup>absorbance values. VL diagnosis was established for 142 (44.1%)<sup> </sup>patients in the VL-symptomatic group (n = 322), based on positive<sup> </sup>microscopy for Leishmania donovani in lymph node aspirates or<sup> </sup>positive DAT (titer,
1:3,200). Of the 125 sera from the symptomatic<sup> </sup>patients for whom microscopy was positive for VL, 111 (88.8%)<sup> </sup>had comparable positive DAT and β-ME ELISA readings. In<sup> </sup>all 17 sera from the symptomatic DAT-positive patients for whom<sup> </sup>leishmaniasis was not established by microscopy but who responded<sup> </sup>favorably to antileishmanial therapy, absorbance values (
0.27)<sup> </sup>indicative of VL were obtained by β-ME ELISA. Of 197 symptomatic<sup> </sup>patients for whom microscopy was negative for VL, 172 (87.3%)<sup> </sup>tested negative in β-ME ELISA and 180 (91.4%) in DAT. Based<sup> </sup>on the high reliability demonstrated here for VL detection,<sup> </sup>β-ME ELISA fulfills the requirement of confirming DAT results<sup> </sup>in patients manifesting suspected VL.
http://cvi.asm.org/cgi/content/abstract/14/12/1592
1071-412X/07/$08.00+0 doi:10.1128/CVI.00313-07
Copyright ? 2007, American Society for Microbiology. All Rights Reserved. [/SIZE]
Use of a Newly Developed β-Mercaptoethanol Enzyme-Linked Immunosorbent Assay To Diagnose Visceral Leishmaniasis in Patients in Eastern Sudan<sup>
Durria Mansour, Elfadil M. Abass, Mohamed el Mutasim,<sup>
Received 26 July 2007/ Returned for modification 12 September 2007/ Accepted 2 October 2007
<!-- ABS --> Corroboration of serology results is essential for restricting<sup> </sup>the risk of inappropriate antileishmanial prescription. A direct<sup> </sup>agglutination test (DAT) and a recently developed β-mercaptoethanol-modified<sup> </sup>enzyme-linked immunosorbent assay (β-ME ELISA) based on<sup> </sup>the use of antigen prepared as described for the DAT were applied<sup> </sup>to 416 sera from two Sudanese populations with and without clinical<sup> </sup>evidence of visceral leishmaniasis (VL). Of 285 sera with the<sup> </sup>lowest antileishmanial DAT titers (
http://cvi.asm.org/cgi/content/abstract/14/12/1592